aclidinium bromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4484	320345-99-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aclidinium bromide Tudorza Pressair aclidinium LAS 34273 LAS W-330	a long-acting, inhaled antimuscarinic; in phase I trial 8/2008 Molecular weight: 484.65 Formula: C26H30NO4S2 CLOGP: 2.34 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 55.76 ALOGS: -5.53 ROTB: 10 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aclidinium bromide
Tudorza Pressair
aclidinium
LAS 34273
LAS W-330

a long-acting, inhaled antimuscarinic; in phase I trial 8/2008

Molecular weight: 484.65
Formula: C26H30NO4S2
CLOGP: 2.34
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 55.76
ALOGS: -5.53
ROTB: 10

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.64	mg	Inhal.powder

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	48.50 mL/min/kg	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 20, 2012	EMA
July 23, 2012	FDA	ASTRAZENECA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	405.95	28.49	243	8915	112527	56170382
Obstructive airways disorder	368.25	28.49	129	9029	17153	56265756
Wheezing	252.26	28.49	155	9003	74871	56208038
Bronchiectasis	197.03	28.49	73	9085	11361	56271548
Nasal polyps	177.90	28.49	50	9108	3215	56279694
Device malfunction	172.65	28.49	73	9085	16063	56266846
Chronic obstructive pulmonary disease	154.06	28.49	103	9055	57312	56225597
Dyspnoea	153.42	28.49	312	8846	592265	55690644
Productive cough	139.24	28.49	96	9062	56136	56226773
Sputum discoloured	121.47	28.49	55	9103	14237	56268672
Full blood count abnormal	121.43	28.49	67	9091	26395	56256514
Asthma-chronic obstructive pulmonary disease overlap syndrome	114.58	28.49	26	9132	695	56282214
Polymyalgia rheumatica	114.17	28.49	35	9123	3047	56279862
Cough	113.94	28.49	173	8985	259788	56023121
Hyper IgE syndrome	110.08	28.49	23	9135	413	56282496
Urinary tract discomfort	109.58	28.49	22	9136	321	56282588
Total lung capacity increased	102.11	28.49	25	9133	934	56281975
Restrictive pulmonary disease	99.89	28.49	27	9131	1499	56281410
Alveolar osteitis	98.25	28.49	22	9136	553	56282356
Tunnel vision	89.77	28.49	22	9136	825	56282084
Myopathy	87.31	28.49	39	9119	9773	56273136
Gastrooesophageal reflux disease	81.28	28.49	83	9075	83174	56199735
Animal scratch	79.89	28.49	21	9137	1047	56281862
Bronchopulmonary aspergillosis allergic	78.10	28.49	22	9136	1424	56281485
Blood iron decreased	77.93	28.49	39	9119	12588	56270321
Breath sounds abnormal	77.59	28.49	35	9123	8972	56273937
Sinus pain	76.62	28.49	25	9133	2663	56280246
Bladder pain	72.70	28.49	22	9136	1832	56281077
Polycystic ovaries	71.49	28.49	25	9133	3289	56279620
Bronchitis chronic	70.64	28.49	26	9132	3962	56278947
Ear congestion	69.24	28.49	22	9136	2153	56280756
Pneumonia	68.95	28.49	182	8976	406916	55875993
Limb injury	64.62	28.49	42	9116	22228	56260681
Type 2 diabetes mellitus	63.42	28.49	56	9102	46806	56236103
Occupational asthma	63.41	28.49	12	9146	126	56282783
Neurosensory hypoacusis	63.27	28.49	13	9145	214	56282695
Blood test abnormal	63.14	28.49	34	9124	12750	56270159
Sarcoidosis	62.62	28.49	26	9132	5454	56277455
Sinus disorder	62.37	28.49	40	9118	20694	56262215
Wound complication	61.40	28.49	22	9136	3106	56279803
Paranasal sinus discomfort	59.70	28.49	22	9136	3363	56279546
Middle insomnia	59.38	28.49	31	9127	10919	56271990
Emphysema	59.18	28.49	30	9128	9946	56272963
Dyslipidaemia	58.92	28.49	26	9132	6327	56276582
Drug dependence	56.95	28.49	39	9119	22494	56260415
Product quality issue	55.52	28.49	44	9114	31692	56251217
Wound secretion	55.43	28.49	22	9136	4112	56278797
Skin lesion	53.54	28.49	41	9117	28094	56254815
Oesophageal dilatation	52.34	28.49	12	9146	336	56282573
Chest discomfort	52.18	28.49	72	9086	98785	56184124
Choking	50.30	28.49	26	9132	8971	56273938
Coronary artery disease	50.27	28.49	41	9117	30755	56252154
Lipohypertrophy	50.19	28.49	13	9145	611	56282298
Therapeutic product effect incomplete	49.73	28.49	73	9085	105958	56176951
Forced expiratory volume decreased	49.53	28.49	21	9137	4639	56278270
Rhinitis allergic	48.85	28.49	25	9133	8449	56274460
Lung neoplasm malignant	48.49	28.49	32	9126	17364	56265545
Pneumothorax spontaneous	47.65	28.49	13	9145	747	56282162
Female sterilisation	47.21	28.49	12	9146	523	56282386
Body temperature increased	44.49	28.49	40	9118	34202	56248707
Glaucoma	43.80	28.49	30	9128	17299	56265610
Intentional device misuse	43.58	28.49	12	9146	714	56282195
Eosinophilia	42.07	28.49	31	9127	20046	56262863
Cardiac murmur	41.91	28.49	25	9133	11376	56271533
Sleep disorder due to a general medical condition	41.62	28.49	23	9135	9067	56273842
Breast conserving surgery	40.73	28.49	12	9146	911	56281998
Angioplasty	40.45	28.49	13	9145	1319	56281590
Rheumatoid arthritis	40.12	28.49	7	9151	382597	55900312
Breast neoplasm	40.04	28.49	13	9145	1363	56281546
Eczema	38.90	28.49	33	9125	26120	56256789
Stress urinary incontinence	37.96	28.49	14	9144	2144	56280765
Rales	37.86	28.49	23	9135	10817	56272092
Vital capacity decreased	36.79	28.49	12	9146	1276	56281633
Hypoaesthesia oral	36.73	28.49	23	9135	11408	56271501
Device failure	36.51	28.49	18	9140	5621	56277288
Crepitations	35.67	28.49	19	9139	6965	56275944
Blood urine present	35.53	28.49	24	9134	13531	56269378
Abscess	35.52	28.49	25	9133	15056	56267853
Influenza	35.48	28.49	59	9099	95202	56187707
Restless legs syndrome	35.13	28.49	26	9132	16921	56265988
Sleep apnoea syndrome	34.95	28.49	31	9127	26030	56256879
Hypokinesia	34.35	28.49	23	9135	12780	56270129
Kyphosis	33.50	28.49	13	9145	2289	56280620
Bronchitis	33.36	28.49	63	9095	112248	56170661
Lung opacity	33.28	28.49	13	9145	2328	56280581
Macrocytosis	33.15	28.49	13	9145	2353	56280556
Heart rate increased	32.93	28.49	53	9105	83220	56199689
Adenocarcinoma	31.10	28.49	13	9145	2772	56280137
Joint swelling	31.03	28.49	5	9153	289795	55993114
Granulomatosis with polyangiitis	30.97	28.49	12	9146	2103	56280806
Presbyacusis	30.86	28.49	13	9145	2825	56280084
Obstructive pancreatitis	30.74	28.49	8	9150	383	56282526
Bronchial wall thickening	30.60	28.49	10	9148	1070	56281839
Dyspnoea exertional	30.60	28.49	41	9117	54648	56228261
Peripheral vascular disorder	30.44	28.49	16	9142	5709	56277200
Nausea	30.01	28.49	49	9109	764129	55518780
Lower respiratory tract infection	29.98	28.49	61	9097	114733	56168176
Hypoacusis	29.40	28.49	26	9132	21742	56261167
Skin laceration	29.09	28.49	25	9133	20131	56262778
Painful respiration	28.96	28.49	12	9146	2502	56280407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic obstructive pulmonary disease	149.50	26.22	86	4138	45080	31648040
Dyspnoea	131.66	26.22	192	4032	343287	31349833
Asthma	130.04	26.22	77	4147	42534	31650586
Device malfunction	111.11	26.22	43	4181	9223	31683897
Wheezing	96.76	26.22	60	4164	35926	31657194
Obstructive airways disorder	69.92	26.22	34	4190	12630	31680490
Intentional device misuse	68.32	26.22	13	4211	175	31692945
Mycobacterium test positive	58.86	26.22	13	4211	377	31692743
Productive cough	56.73	26.22	42	4182	33498	31659622
Lung diffusion test decreased	53.37	26.22	13	4211	583	31692537
Product quality issue	51.35	26.22	30	4194	16081	31677039
Nephrectomy	45.37	26.22	12	4212	751	31692369
Carotid arteriosclerosis	43.53	26.22	14	4210	1743	31691377
Bronchiolitis	40.27	26.22	15	4209	2889	31690231
Breath sounds abnormal	39.14	26.22	18	4206	5894	31687226
Lower respiratory tract infection	38.22	26.22	31	4193	28206	31664914
Chest discomfort	37.11	26.22	39	4185	49330	31643790
Obstruction	37.01	26.22	13	4211	2119	31691001
Lung diffusion disorder	36.73	26.22	7	4217	95	31693025
Granuloma	36.59	26.22	14	4210	2903	31690217
Pulmonary mass	35.88	26.22	21	4203	11285	31681835
Device issue	35.78	26.22	19	4205	8465	31684655
Dyspnoea exertional	35.28	26.22	34	4190	38803	31654317
Cough	34.25	26.22	63	4161	134751	31558369
Bronchial obstruction	33.59	26.22	11	4213	1449	31691671
Full blood count abnormal	31.10	26.22	22	4202	16325	31676795
Fungal disease carrier	30.15	26.22	7	4217	255	31692865
Inguinal hernia repair	29.78	26.22	7	4217	269	31692851
Device failure	29.56	26.22	11	4213	2112	31691008
Sleep disorder due to a general medical condition	29.38	26.22	13	4211	3889	31689231
Blood immunoglobulin E increased	29.03	26.22	11	4213	2220	31690900
Atrial fibrillation	28.66	26.22	53	4171	113730	31579390
Loss of personal independence in daily activities	28.04	26.22	26	4198	28262	31664858
Renal cyst	27.67	26.22	16	4208	8400	31684720
Therapeutic product effect incomplete	26.74	26.22	31	4193	43665	31649455
Bronchiectasis	26.50	26.22	15	4209	7565	31685555

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	473.78	24.64	275	11235	120518	70796416
Obstructive airways disorder	347.71	24.64	138	11372	25975	70890959
Wheezing	272.99	24.64	177	11333	93993	70822941
Chronic obstructive pulmonary disease	220.16	24.64	144	11366	77497	70839437
Bronchiectasis	206.96	24.64	83	11427	16014	70900920
Nasal polyps	187.69	24.64	56	11454	4460	70912474
Dyspnoea	183.11	24.64	391	11119	769669	70147265
Productive cough	153.66	24.64	116	11394	78221	70838713
Urinary tract discomfort	120.39	24.64	25	11485	436	70916498
Cough	117.43	24.64	198	11312	325179	70591755
Alveolar osteitis	114.54	24.64	25	11485	558	70916376
Polymyalgia rheumatica	114.35	24.64	37	11473	3849	70913085
Hyper IgE syndrome	107.13	24.64	23	11487	474	70916460
Breath sounds abnormal	106.50	24.64	49	11461	13182	70903752
Full blood count abnormal	106.19	24.64	67	11443	33811	70883123
Sputum discoloured	104.20	24.64	54	11456	18797	70898137
Device malfunction	103.57	24.64	54	11456	19030	70897904
Restrictive pulmonary disease	101.94	24.64	30	11480	2276	70914658
Total lung capacity increased	97.45	24.64	24	11486	921	70916013
Tunnel vision	95.96	24.64	25	11485	1206	70915728
Animal scratch	92.36	24.64	24	11486	1146	70915788
Asthma-chronic obstructive pulmonary disease overlap syndrome	90.03	24.64	25	11485	1539	70915395
Bronchopulmonary aspergillosis allergic	88.72	24.64	26	11484	1943	70914991
Sinus pain	85.35	24.64	28	11482	3041	70913893
Myopathy	85.11	24.64	47	11463	18565	70898369
Blood iron decreased	85.02	24.64	42	11468	13219	70903715
Bladder pain	83.91	24.64	25	11485	1979	70914955
Ear congestion	80.22	24.64	25	11485	2302	70914632
Polycystic ovaries	75.05	24.64	25	11485	2847	70914087
Chest discomfort	71.03	24.64	94	11416	124287	70792647
Paranasal sinus discomfort	69.97	24.64	25	11485	3510	70913424
Limb injury	68.59	24.64	46	11464	25706	70891228
Sinus disorder	68.32	24.64	41	11469	18918	70898016
Type 2 diabetes mellitus	66.49	24.64	56	11454	44024	70872910
Wound complication	65.14	24.64	25	11485	4284	70912650
Lower respiratory tract infection	64.54	24.64	85	11425	111828	70805106
Gastrooesophageal reflux disease	63.55	24.64	76	11434	90763	70826171
Sleep disorder due to a general medical condition	60.74	24.64	31	11479	10445	70906489
Emphysema	60.65	24.64	35	11475	15025	70901909
Middle insomnia	60.19	24.64	34	11476	14019	70902915
Wound secretion	58.91	24.64	25	11485	5550	70911384
Neurosensory hypoacusis	57.64	24.64	12	11498	212	70916722
Sarcoidosis	54.76	24.64	25	11485	6602	70910332
Blood test abnormal	53.73	24.64	32	11478	14558	70902376
Forced expiratory volume decreased	52.40	24.64	25	11485	7289	70909645
Mycobacterium test positive	50.10	24.64	12	11498	409	70916525
Rhinitis allergic	49.56	24.64	26	11484	9269	70907665
Choking	48.02	24.64	27	11483	11033	70905901
Drug dependence	47.40	24.64	43	11467	37278	70879656
Dyslipidaemia	45.35	24.64	25	11485	9835	70907099
Body temperature increased	45.00	24.64	43	11467	39791	70877143
Breast conserving surgery	44.53	24.64	12	11498	660	70916274
Pneumothorax spontaneous	44.40	24.64	14	11496	1339	70915595
Bronchitis	44.31	24.64	73	11437	117170	70799764
Kyphosis	43.75	24.64	16	11494	2400	70914534
Pneumonia	43.19	24.64	201	11309	596031	70320903
Therapeutic product effect incomplete	43.12	24.64	73	11437	119809	70797125
Lipohypertrophy	41.75	24.64	12	11498	837	70916097
Pulmonary mass	41.17	24.64	34	11476	25999	70890935
Breast neoplasm	41.03	24.64	12	11498	890	70916044
Skin lesion	40.60	24.64	40	11470	38420	70878514
Angioplasty	40.48	24.64	14	11496	1786	70915148
Hypoaesthesia oral	40.21	24.64	25	11485	12275	70904659
Crepitations	39.81	24.64	22	11488	8692	70908242
Rales	39.48	24.64	28	11482	17107	70899827
Intentional device misuse	39.38	24.64	11	11499	692	70916242
Lung neoplasm malignant	38.47	24.64	32	11478	24710	70892224
Hypercapnia	37.98	24.64	21	11489	8308	70908626
Cardiac murmur	37.91	24.64	24	11486	12162	70904772
Heart rate increased	37.32	24.64	64	11446	106084	70810850
Eczema	37.28	24.64	36	11474	33745	70883189
Lung diffusion test decreased	37.22	24.64	12	11498	1233	70915701
Coronary artery disease	36.68	24.64	48	11462	62688	70854246
Sleep apnoea syndrome	36.36	24.64	35	11475	32678	70884256
Joint injury	36.11	24.64	32	11478	26900	70890034
Dyspnoea exertional	35.41	24.64	53	11457	78377	70838557
Influenza	35.40	24.64	65	11445	113635	70803299
Hypokinesia	34.53	24.64	26	11484	17406	70899528
Blood urine present	34.25	24.64	27	11483	19326	70897608
Toxicity to various agents	33.89	24.64	10	11500	382162	70534772
Rheumatoid arthritis	33.55	24.64	4	11506	291801	70625133
Carotid arteriosclerosis	32.86	24.64	13	11497	2414	70914520
Lung diffusion disorder	32.75	24.64	7	11503	141	70916793
Product quality issue	32.65	24.64	32	11478	30529	70886405
Procedural pain	31.61	24.64	25	11485	17984	70898950
Skin laceration	31.27	24.64	29	11481	25849	70891085
Restless legs syndrome	31.10	24.64	25	11485	18403	70898531
Neutropenia	30.90	24.64	3	11507	257153	70659781
Bronchiolitis	30.29	24.64	14	11496	3800	70913134
Nephrectomy	29.19	24.64	11	11499	1792	70915142
Peripheral vascular disorder	28.78	24.64	17	11493	7615	70909319
Abscess	28.61	24.64	25	11485	20629	70896305
Inguinal hernia repair	28.54	24.64	7	11503	264	70916670
Nausea	28.45	24.64	60	11450	852028	70064906
Presbyacusis	28.44	24.64	12	11498	2625	70914309
Oral candidiasis	28.30	24.64	27	11483	24925	70892009
Macrocytosis	28.05	24.64	12	11498	2715	70914219
Feeling cold	27.74	24.64	27	11483	25543	70891391
Off label use	27.68	24.64	49	11461	743011	70173923
Fungal disease carrier	27.60	24.64	7	11503	303	70916631
Bronchial wall thickening	27.17	24.64	11	11499	2168	70914766
Panic attack	27.13	24.64	25	11485	22094	70894840
Disability	26.72	24.64	21	11489	14962	70901972
Influenza like illness	26.46	24.64	42	11468	65289	70851645
Hypoacusis	26.28	24.64	27	11483	27242	70889692
Confusional state	26.02	24.64	7	11503	284391	70632543
Joint swelling	25.62	24.64	5	11505	253206	70663728
Granulomatosis with polyangiitis	25.29	24.64	11	11499	2591	70914343
Movement disorder	25.28	24.64	25	11485	24104	70892830
Lung consolidation	24.94	24.64	16	11494	8290	70908644
Obstruction	24.73	24.64	12	11498	3629	70913305
Adenocarcinoma	24.69	24.64	12	11498	3641	70913293
Chronic sinusitis	24.69	24.64	16	11494	8435	70908499
Device failure	24.67	24.64	14	11496	5821	70911113

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R03AL05	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BB05	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:48876	muscarinic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic obstructive lung disease	indication	13645005	DOID:3083

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.97	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.4MG/INH	TUDORZA PRESSAIR	COVIS	N202450	July 23, 2012	RX	POWDER, METERED	INHALATION	RE46417	Feb. 10, 2025	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.4MG/INH;0.012MG/INH	DUAKLIR PRESSAIR	COVIS	N210595	March 29, 2019	RX	POWDER, METERED	INHALATION	RE46417	Feb. 10, 2025	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.4MG/INH	TUDORZA PRESSAIR	COVIS	N202450	July 23, 2012	RX	POWDER, METERED	INHALATION	10085974	March 13, 2029	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.4MG/INH	TUDORZA PRESSAIR	COVIS	N202450	July 23, 2012	RX	POWDER, METERED	INHALATION	11000517	March 13, 2029	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.4MG/INH;0.012MG/INH	DUAKLIR PRESSAIR	COVIS	N210595	March 29, 2019	RX	POWDER, METERED	INHALATION	10085974	March 13, 2029	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.4MG/INH;0.012MG/INH	DUAKLIR PRESSAIR	COVIS	N210595	March 29, 2019	RX	POWDER, METERED	INHALATION	11000517	March 13, 2029	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.4MG/INH	TUDORZA PRESSAIR	COVIS	N202450	July 23, 2012	RX	POWDER, METERED	INHALATION	March 29, 2022	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
0.4MG/INH;0.012MG/INH	DUAKLIR PRESSAIR	COVIS	N210595	March 29, 2019	RX	POWDER, METERED	INHALATION	March 29, 2022	NEW COMBINATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	10.15	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	10.10	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	10.10	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		IC50	9.70	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		IC50	9.80	CHEMBL

External reference:

ID	Source
D08837	KEGG_DRUG
4031720	VUID
N0000185730	NUI
4031719	VANDF
4031720	VANDF
CHEBI:65344	CHEBI
CHEMBL551466	ChEMBL_ID
C542859	MESH_SUPPLEMENTAL_RECORD_UI
7449	IUPHAR_LIGAND_ID
8544	INN_ID
727649-81-2	SECONDARY_CAS_RN
UQW7UF9N91	UNII
DB08897	DRUGBANK_ID
1303097	RXNORM
192177	MMSL
28687	MMSL
d07885	MMSL
014613	NDDF
014614	NDDF
703921008	SNOMEDCT_US
703922001	SNOMEDCT_US
703923006	SNOMEDCT_US
C2699758	UMLSCUI
CHEMBL1194325	ChEMBL_ID
11519741	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tudorza Pressair	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0800	POWDER, METERED	400 ug	RESPIRATORY (INHALATION)	NDA	27 sections
DUAKLIR PRESSAIR	HUMAN PRESCRIPTION DRUG LABEL	2	0310-0900	POWDER, METERED	400 ug	RESPIRATORY (INHALATION)	NDA	27 sections
DUAKLIR PRESSAIR	HUMAN PRESCRIPTION DRUG LABEL	2	72124-001	POWDER, METERED	400 ug	RESPIRATORY (INHALATION)	NDA	26 sections
Tudorza Pressair	HUMAN PRESCRIPTION DRUG LABEL	1	72124-002	POWDER, METERED	400 ug	RESPIRATORY (INHALATION)	NDA	28 sections